Last reviewed · How we verify
IFN-gamma
IFN-gamma, marketed by the National Institute of Allergy and Infectious Diseases (NIAID), holds a niche position in the therapeutic landscape. The drug's key composition patent is set to expire in 2028, providing a period of exclusivity that supports its market presence. The primary risk is the lack of clear revenue data and key trial results, which may limit its commercial appeal and strategic planning.
At a glance
| Generic name | IFN-gamma |
|---|---|
| Also known as | Interferon-gamma |
| Sponsor | National Institute of Allergy and Infectious Diseases (NIAID) |
| Modality | Small molecule |
| Phase | FDA-approved |